MétaCan
Menu
← Back to cohort

AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

2023· article· en· W4379282075 on OpenAlexaff
Pooya Mobadersany, Shaozhou K. Tian, Stephen Yip, Joel Greshock, Najat Khan, Margaret K. Yu, Sharon McCarthy, Sabine Brookman‐May, Muhammad Hassan, Chensu Xie, Wei Huang, Hirak S. Basu, George Wilding, Parag Jain, Rajat Roy, Eric J. Small, Fred Saad, Matthew R. Smith

Bibliographic record

VenueJournal of Clinical Oncology · 2023
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsCentre Hospitalier de l’Université de Montréal
FundersJanssen Research and Development
KeywordsMedicineProstate cancerMetastasisProstatectomyOncologyInternal medicineAndrogen deprivation therapyCancerProstatePlaceboDiseaseUrologyPathology

Abstract

fetched live from OpenAlex

5027 Background: Most prostate cancer patients (pts) treated with androgen deprivation therapy (ADT) for progressive disease will experience progression to CRPC. APA has been approved for the treatment of nmCRPC and metastatic castration sensitive prostate cancer (mCSPC). AI-enabled tools developed to predict oncological outcomes from digitized whole-slide images (WSIs) of H&E-stained tissues are a practical alternative to costly genomic testing tools that require sufficient tumor material. PathomIQ has developed the AI-enabled prognostic test PRAD-DX that predicts risk of metastasis from WSIs of H&E-stained core biopsies or radical prostatectomy specimens. It has been validated as a research tool on more than 2000 tissue samples across multiple institutions. The objective of this study is to evaluate PRAD-DX on predicting risk of metastatic progression using archived primary tumor samples from a randomized, double-blind, phase 3 trial in nmCRPC pts [1]. Methods: WSIs were collected from 471 pts (APA+ADT (n=315); placebo+ADT (n=156)), de-identified and anonymized prior to the AI analysis. Patient outcomes were blinded to the PathomIQ team. 35 pts were excluded due to lack of tumor or poor image quality; PRAD-DX scores were generated for 436 (93%) pts. The PRAD-DX test generated a risk score for each patient between 0 and 1, with higher values representing increased risk of metastasis. A pre-determined cut-off of 0.55 was previously developed to provide the best predictive accuracy and stratification with respect to time-to-metastasis on multiple clinical cohorts and was applied to this dataset. Kaplan-Meier analysis was performed on Metastasis-free-survival (MFS). Results: All pts receiving APA+ADT had improved outcomes compared with pts receiving ADT alone, independent of PRAD-DX risk score category. 53% of pts had high PRAD-DX scores and significantly benefited from treatment with APA+ADT compared to placebo+ADT with regard to MFS (hazard ratio, 0.19; 95% CI, 0.1 – 0.37; P<0.005). 47% were assigned low PRAD-DX risk; also in this cohort, treatment with APA+ADT resulted in a significantly improved MFS (hazard ratio, 0.39; 95% CI, 0.17 – 0.86; P=0.02). Conclusions: These results indicate that PRAD-DX score derived from AI-powered image analysis could be used as a biomarker to identify pts at highest risk of metastatic progression in the nmCRPC setting. Although, there are limitations related to sample size, this may have significant impact in identifying pts for informed clinical trial patient selection based on their individual risk profile for development of novel therapies. 1) Smith MR, Saad F, Chowdhury S, et al. N Engl J Med. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.114
GPT teacher head0.515
Teacher spread0.401 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→